scispace - formally typeset
A

Alfredo Caturano

Researcher at Seconda Università degli Studi di Napoli

Publications -  51
Citations -  816

Alfredo Caturano is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 7, co-authored 25 publications receiving 117 citations.

Papers
More filters
Journal ArticleDOI

The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy.

TL;DR: National and international guidelines should consider its inclusion in their updates, and the deployment of device and digital application used to increase screening of individuals and monitor progression of retinal disease needs to be easily accessible to general practitioners.
Journal ArticleDOI

Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review.

TL;DR: In this paper, the authors consider the risk of metabolic syndrome as a risk factor for cardiovascular disease, regardless of age, sex, smoking habit, cholesterolemia, and other elements of MS, and suggest that lifestyle modifications (diet, physical exercise, and weight loss) determine an improvement in IR, MS and both clinical and histologic liver picture.
Journal ArticleDOI

Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects

TL;DR: In this paper, a review of metformin's beneficial effects on endothelium-dependent vascular response in type 2 diabetes patients is presented, which could preempt development of atherosclerosis.
Journal ArticleDOI

Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact

TL;DR: The role of diet, intestinal microbiota, genetic and epigenetic factors, low-degree chronic systemic inflammation, mitochondrial dysfunction, and endoplasmic reticulum stress on NAFLD have been addressed and its direct link with type 2 diabetes have been discussed.
Journal ArticleDOI

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors

TL;DR: Correcting cardiorenal risk factors, metabolic adjustments ameliorating myocardial substrate utilization, and optimization of ventricular loading conditions through effects on diuresis, natriureis, and vascular function appear to be the main underlying mechanisms for the observed cardi Lorenal protection.